Harmony Biosciences

Update in progress

HRMY (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on rare neurological diseases in the United States. It markets WAKIX (pitolisant) for excessive daytime sleepiness in adults with narcolepsy and develops multiple programs, including BP1.15205 (orexin 2 receptor agonist), HBS-102 (MCHR1 antagonist), and ZYN-002 for Fragile X and 22q Deletion. It also advances EPX-100, EPX-200, CBS105, and CBS104, plus other earlier-stage products. Formerly Harmony Biosciences II, it changed its name in 2020. Founded in 2017, it is headquartered in Plymouth Meeting, Pennsylvania.

Company score

Sentiment: -0.03; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.02; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive